Adam Laponis - 21 Aug 2025 Form 4 Insider Report for Twist Bioscience Corp (TWST)

Role: Chief Financial Officer
Signature: /s/ Kendra Fox, as Attorney-in-Fact for Adam Laponis
Issuer symbol: TWST
Transactions as of: 21 Aug 2025
Net transactions value: -$23,835
Form type: 4
Filing time: 25 Aug 2025, 16:05:24 UTC
Previous filing: 11 Jul 2025
Next filing: 08 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Laponis Adam	Chief Financial Officer	C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD, SOUTH SAN FRANCISCO	/s/ Kendra Fox, as Attorney-in-Fact for Adam Laponis	25 Aug 2025	0001827198

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TWST	Common Stock	Sale	$23,835	-918	-0.88%	$25.96	102,917	21 Aug 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F2	Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Content

Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).